...
首页> 外文期刊>RSC Advances >Supramolecular prodrug micelles based on the complementary multiple hydrogen bonds as drug delivery platform for thrombosis therapy
【24h】

Supramolecular prodrug micelles based on the complementary multiple hydrogen bonds as drug delivery platform for thrombosis therapy

机译:基于互补多氢键作为血栓形成治疗的药物递送平台的超分子前药胶束

获取原文

摘要

To improve the effect of thrombosis therapy, an amphiphilic supramolecular prodrug consisting of diosgenin derivative (theophylline–diosgenin) and uracil-terminated poly(ethylene glycol) (PEG-U) was designed and synthesized successfully. The prodrug could self-assemble into micelles which was not only enhanced the drug solubility but also prolonged systemic circulation. Bleeding time assay confirmed that the micelles have a better antithrombotic activity compared to diosgenin in vivo , and platelet aggregation assay in vitro got the same results. The low cytotoxicity of supramolecular copolymer micelles was confirmed by MTT assay against LO2/HK-2 cells and acute toxicity studies in mice. Based on these results, the supramolecular prodrug micelles are very promising candidates for thrombosis therapy.
机译:为了提高血栓形成疗法的效果,设计并成功地设计了由DioSgen衍生物(Theophylline-Diosgenin)和尿嘧啶封端的聚(乙二醇)(PEG-U)组成的两亲的超分子前药。前药可以自组装成胶束,这不仅增强了药物溶解度,而且延长了全身循环。出血时间测定证实,与体内的二氧吡蛋白相比,胶束具有更好的抗血栓活性,并且体外血小板聚集测定得到相同的结果。通过MTT测定法证实了超分子共聚物胶束的低细胞毒性,对小鼠的LO2 / HK-2细胞和急性毒性研究证实。基于这些结果,超分子前药胶束是血栓形成治疗的非常有希望的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号